Department of Pharmacy, AP-HP, Robert-Debré Hospital, Paris, France.
UMR-S1123, ECEVE; Inserm U1123, INSERM, Paris, Île-de-France, France.
BMJ Open. 2019 Mar 20;9(3):e019186. doi: 10.1136/bmjopen-2017-019186.
Pediatrics: Omission of Prescription and Inappropriate prescription (POPI) is the first detection tool for potentially inappropriate medicines (PIMs) and potentially prescribing omissions (PPOs) in paediatrics. The aim of this study was to evaluate the prevalence of PIM and PPO detected by POPI regarding prescriptions in hospital and for outpatients. The second objective is to determine the risk factors related to PIM and PPO.
A retrospective, descriptive study was conducted in the emergency department (ED) and community pharmacy (CP) during 6 months. POPI was used to identify PIM and PPO.
Robert-Debré Hospital (France) and Albaret community pharmacy (Seine and Marne).
Patients who were under 18 years old and who had one or more drugs prescribed were included. Exclusion criteria consisted of inaccessible medical records for patients consulted in ED and prescription without drugs for outpatients.
PIM and PPO rate and risk factors.
At the ED, 18 562 prescriptions of 15 973 patients and 4780 prescriptions of 2225 patients at the CP were analysed. The PIM rate and PPO rate were, respectively, 2.9% and 2.3% at the ED and 12.3% and 6.1% at the CP. Respiratory and digestive diseases had the highest rate of PIM.
This is the first study to assess the prevalence of PIM and PPO detected by POPI in a paediatric population. This study assessed PIMs or PPOs within a hospital and a community pharmacy. POPI could be used to improve drug use and patient care and to limit hospitalisation and adverse drug reaction. A prospective multicentric study should be conducted to evaluate the impact and benefit of implementing POPI in clinical practice.
儿科:处方遗漏和不适当处方(POPI)是检测儿科潜在不适当药物(PIM)和潜在处方遗漏(PPO)的第一个工具。本研究旨在评估 POPI 检测到的医院和门诊处方中 PIM 和 PPO 的发生率。第二个目的是确定与 PIM 和 PPO 相关的风险因素。
这是一项在急诊部(ED)和社区药房(CP)进行的为期 6 个月的回顾性描述性研究。使用 POPI 识别 PIM 和 PPO。
法国罗伯特·德布雷医院(Robert-Debré Hospital)和塞纳-马恩省阿尔巴雷社区药房(Albaret community pharmacy)。
纳入年龄在 18 岁以下且有 1 种或多种药物处方的患者。排除标准包括 ED 就诊的患者病历无法获取以及门诊患者的处方不含药物。
PIM 和 PPO 的发生率和风险因素。
在 ED,分析了 15973 名患者的 18562 张处方和 2225 名患者的 4780 张处方;CP 中 PIM 和 PPO 的发生率分别为 2.9%和 2.3%和 12.3%和 6.1%。呼吸道和消化系统疾病的 PIM 发生率最高。
这是第一项评估 POPI 检测儿科人群中 PIM 和 PPO 发生率的研究。这项研究评估了医院和社区药房中的 PIM 和 PPO。POPI 可用于改善药物使用和患者护理,限制住院和药物不良反应。应进行前瞻性多中心研究,以评估在临床实践中实施 POPI 的影响和益处。